An observational study in Interstitial Lung Disease and Myositis, sponsored by Singapore General Hospital. Recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Singapore General Hospital · Observational
Idiopathic inflammatory myopathies (IIM) are a group of autoimmune conditions characterized by inflammation of muscles with possible extra-muscular manifestations which can include skin and interstitial lung disease (ILD). IIM-associated ILD carries poor prognosis. Particular subtypes of IIM such as anti-melanoma differentiation-associated protein 5 positive (anti-MDA5+) dermatomyositis with ILD are most commonly associated with rapidly progressive-interstitial lung disease (RP-ILD). RP-ILD is defined as worsening dyspnoea on exertion, hypoxaemia, and presence of newly emerging or expanding ground glass opacities on radiographic or computed topography of chest imaging excluding drug or infectious cause. Particularly, patients with anti-MDA5+ dermatomyositis often have RP-ILD with high mortality of over 60% in the first six months of diagnosis. The mainstay of treatment is immunosuppression though there has been no highly efficacious therapy proven to date. Therefore, the overall goal is to improve patient outcomes in IIM-associated RP-ILD including those with anti-MDA5+ dermatomyositis through the development of better treatment regimens. The objective of this research study is to evaluate the efficacy and safety of a combined immunosuppressive regime in patients with IIM-associated RP-ILD. The investigators hypothesize that the simultaneous inhibition of particular targets in the innate and adaptive immune system will improve efficacy and patient survival. The approach involves a combination of four immunosuppressive medications targeting different pathways implicated in IIM associated ILD. If successful, this study could contribute significantly to improving clinical outcomes for patients with IIM-associated RP-ILD.
The primary feature of idiopathic inflammatory myopathies (IIM) is inflammation of muscles, yet extra-muscular manifestations are common such as interstitial lung disease (ILD). Based on both muscular and extra-muscular features, patients can fall into different types of IIMs, including broad subtypes of dermatomyositis (DM), polymyositis (PM), inclusion-body myositis (IBM) and immune-mediating necrotizing myopathies (IMNM). Particular subtypes such as dermatomyositis patients positive for anti-melanoma differentiation-associated protein 5 (anti-MDA5) are most commonly associated with rapidly progressive lung involvement and high mortality, with survival at 1 year being less than 60% despite current available treatment. Treatment for IIM patients involves immunosuppression, though there is no consensus or treatment guidelines available for different subtypes, particularly for myositis-associated RP-ILD. Despite several trials having shown increased efficacy with more aggressive immunosuppressive regimes, mortality still remains high. There is thus an unmet need with regards to treatment of patients with IIM, particularly for myositis-associated RP-ILD.
There is an urgent need to improve outcomes in myositis-associated RP-ILD. Till date, there are no randomised controlled trials that investigate therapy of myositis-associated RP-ILD likely due to the low incidence of the disease. Current best level of evidence for therapies come from single-arm prospective cohort studies with comparison with historical controls. Recent studies using combination therapy to target different aspects of these pathological processes have demonstrated increased efficacy compared to single target alone. This shows that appropriate selection of targets with subsequent combination blockade will be beneficial in treatment of patients with myositis associated RP-ILD. Hence, the investigators propose the utilization of rituximab to block the B-cell involvement, tacrolimus to target T-cells, tofacitinib to block interferon signaling with steroids due to their effects on both the innate and adaptive system in the treatment of myositis-associated RP-ILD. Such combination therapy allows precise targeting of pathways responsible for pathophysiology of the disease, without high individual dosages and hence reducing potential side effects. Till date there are no prospective studies that look into current combination of steroids, tacrolimus, tofacitinib and rituximab in the patients with myositis-associated RP-ILD. However, a drawback for increased immunosuppression is infection, particularly with cytomegalovirus (CMV). The investigators will employ a prophylactic treatment strategy to mitigate the risk of increased infection following higher intensity immunosuppression.
The primary end point will be survival rate at 6 months from initiation of treatment.
Secondary end points include improvement of clinical status, biochemical markers, radiological appearance and parameters on lung function test. Secondary end points also include adverse events rate including side effects from treatment and infection rates.
680 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.
This study's planned enrollment of 80 is below the median of 157 across 278 observational studies indexed under Lung Diseases, Interstitial.
Browse Lung Diseases, Interstitial studies →Singapore General Hospital is the lead sponsor of 270 studies on the registry; 57 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients currently undergoing treatment with combined immunosuppressive treatment for myositis-associated rapidly progressive interstitial lung disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with immune-mediated myositis-associated rapidly progressive interstitial lung disease undergoing treatment with combined immunosuppressive treatment
Drug: Immunosuppressant Regimen
Combination treatment regimen lasting 6 months with A) Steroids: Starting with Intravenous methylprednisolone (500mg once daily for three days) followed by tapering dose of prednisolone B) Rituximab (1000mg given at the start of treatment and 1000mg 2 weeks after the first dose) C) Tacrolimus D) Tofacitinib
Also known as: Tofacitinib, Rituximab, Tacrolimus, Prednisolone
All-cause mortality at 6 months from treatment initiation
Proportion of total participants who demise from all cause till 6 months from treatment initiation (percentage of all participants)
Time frame: 6 months
Change in clinical status through Modified Medical Research Council Dyspnea Scale
The Modified Medical Research Council (mMRC) Dyspnea Scale will be used to rate participants' functional status at start of treatment and at 6 months post treatment (0 to 4).
Time frame: 6 months
Change in clinical status through requirement of supplemental oxygen at 6 months
Proportion of participants who require oxygen supplementation at the start of treatment and 6 months post treatment (percentage of all participants).
Time frame: 6 months
Safety of treatment regimen in participants
Number of adverse infection events experienced by participants
Time frame: 6 months
Safety of treatment regimen in participants
Number of adverse haematological events leading to change of medication as per managing physician
Time frame: 6 months
Safety of treatment regimen in participants
Number of adverse biochemical events leading to change of medication as per managing physician
Time frame: 6 months
Change in biochemical markers of disease activity
Levels of C-reactive protein (mg/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year
Time frame: 1 year
Change in biochemical markers of disease activity
Levels of Erythrocyte sedimentation rate (mm/h) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
Time frame: 1 year
Change in biochemical markers of disease activity
Levels of Ferritin (ug/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
Time frame: 1 year
Change in biochemical markers of disease activity
Levels of Lactate dehydrogenase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
Time frame: 1 year
Change in biochemical markers of disease activity
Levels of Creatine kinase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
Time frame: 1 year
Change in biochemical markers of disease activity
Levels of Aldolase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Jul 2029, 54 months after the start.
Of 111 non-industry observational studies under Lung Diseases, Interstitial, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 274. This study's planned 54 months is below that.
Counting every sponsor, half of 132 studies reached it within 55 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.